Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched control group Clear all
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis

NCT05357755
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • Skokie, Illinois • Overland Park, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function

NCT01715259
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Abiraterone acetate: participants with end-stage renal disease, Abiraterone acetate: matched control participants with normal renal function
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Acceptability of a Single Session of Imagery Rescripting in a Community Sample of Adults

NCT06610318
View directory record Official record
Conditions
Feasibility Studies, Acceptability, Depressive Symptoms, Disordered Eating Behaviors
Interventions
imagery rescripting, nutrition education
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH

NCT03980717
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia
Interventions
Goldbal Detachable Balloon and delivery microcatheter
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Terminated Phase 3 Interventional Results available

Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus

NCT00571519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rivoglitazone HCl, placebo, pioglitazone HCl, pioglitazone HCl 45 mg, metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Huntsville, Alabama • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 30, 2026, 10:59 PM EDT
Not listed Not applicable Interventional

e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions

NCT02087293
View directory record Official record
Conditions
Diabetes, Depression, Insomnia, Hypertension
Interventions
Intervention arm - automated call and phone-based pharmacist counseling
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
38,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 30, 2026, 10:59 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

NCT04380220
View directory record Official record
Conditions
Multiple Sclerosis, Relapse
Interventions
Blood samples and processing
Diagnostic Test
Lead sponsor
Regina Elena Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

NCT04233879
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Lovastatin in Treating Patients At High Risk of Melanoma

NCT00462280
View directory record Official record
Conditions
Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions
lovastatin, placebo, biopsy, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Orange, California • Tampa, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 30, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

NCT07344727
View directory record Official record
Conditions
Inflammation, Oxidative Stress, Resistance Exercise, Recovery, Exercise Performance Recovery
Interventions
Haskap berry smoothie, Placebo Comparator
Dietary Supplement
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Not yet recruiting Not applicable Interventional

Cognitive Training for Functioning in PTSD

NCT07693686
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
COGENT (Cognitive ENhancement Training), ST (Sham Training)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

NCT01596673
View directory record Official record
Conditions
Drug Abuse
Interventions
45-mg hydrocodone bitartrate extended-release tablet (crushed or intact), Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Not applicable Interventional

TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)

NCT01043354
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
stage-matched intervention, framing effects intervention, attention placebo intervention
Behavioral
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
21 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

NCT00942305
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 30, 2026, 10:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

NCT04678505
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3402
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 30, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Weekly Dosing of Malarone ® for Prevention of Malaria

NCT00984256
View directory record Official record
Conditions
Malaria
Interventions
Atovaquone Proguanil, Procedure - malaria challenge
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 30, 2026, 10:59 PM EDT
Completed No phase listed Observational

Chest Dysphoria in Transmasculine Spectrum Adolescents

NCT04195659
View directory record Official record
Conditions
Gender Dysphoria
Interventions
Mastectomy and chest masculinization
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2022 · Synced Oct 30, 2026, 10:59 PM EDT